EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Efficacy of a novel PCSK9 inhibitory peptide alone and with evinacumab in a mouse model of atherosclerosis

José A Inia, Anita van Nieuwkoop-van Straalen, J Wouter Jukema, Bidda Rolin, Ellen Marie Staarup, Christina K Mogensen, Hans M G Princen, Anita M van den Hoek

Journal of Lipid Research · 2025

DOI: 10.1016/j.jlr.2025.100753 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Lipid Research, 2025. Verfasst von José A Inia und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Metabolic Health Research, The Netherlands Organization for Applied Scientific Research (TNO), Leiden, the Netherlands; Department of C…. Hauptthemen laut MEDLINE: Atherosclerosis, Antibodies, Monoclonal, PCSK9 Inhibitors, Peptides. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk, TNO.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atherosclerosis is the major cause of cardiovascular disease. This study evaluated the effect of lipid lowering using a novel peptide inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) and a monoclonal antibody against angiopoietin-like 3 (evinacumab), either alone or in combination in APOE∗3-Leiden.CETP mice fed a Western diet. Effects on body weight, plasma lipids, atherosclerotic lesion size, severity, composition, and morphology were assessed. Treatment with PCSK9 inhibitory peptide significantly decreased both cholesterol and triglycerides (-69% and -68%, respectively). Similar reductions were seen in evinacumab-treated mice (-44% and -55%, respectively). The combination of evinacumab and PCSK9 inhibitory peptide lowered these levels to a larger extent than evinacumab alone (cholesterol: -74%; triglycerides: -81%). Reductions occurred in non-HDL-C without changes in HDL-C. Atherosclerotic lesion size was significantly reduced in all treatment groups compared to vehicle controls (evinacumab: -72%; PCSK9 inhibitory peptide: -97%; combination: -98%). Similarly, all interventions improved atherosclerotic lesion severity, with more undiseased segments and fewer severe lesions. Evaluation of the composition of severe atherosclerotic plaques revealed significant improvement in lesion stability in mice treated with both evinacumab and PCSK9 inhibitory peptide, attributable to decreased macrophage content and increased collagen content. Additionally, evaluation of lipid concentrations in cynomolgus monkeys revealed the beneficial effects of the PCSK9 inhibitory peptide on total cholesterol and LDL-C levels. Treatment with a novel PCSK9 inhibitory peptide alone or with evinacumab shows great potential to reduce and stabilize atherosclerotic lesions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtherosclerosisAntibodies, MonoclonalPCSK9 InhibitorsPeptidesAnimalsMiceDisease Models, AnimalProprotein Convertase 9Male

Stichwörter der Autor:innen

ANGPTL3APOE∗3-Leiden.CETP micePCSK9atherosclerosisatherosclerotic plaque compositioncombination therapyevinacumablipid lowering

Substanzen

Antibodies, MonoclonalPCSK9 InhibitorsevinacumabProprotein Convertase 9Peptides

Autor:innen und Institutionen

  • Department of Metabolic Health Research, The Netherlands Organization for Applied Scientific Research (TNO), Leiden, the Netherlands; Department of Cardiology, Leiden University Medical Centre, Leiden, the Netherlands;…
  • Department of Metabolic Health Research, The Netherlands Organization for Applied Scientific Research (TNO), Leiden, the Netherlands.
  • Department of Cardiology, Leiden University Medical Centre, Leiden, the Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Centre, Leiden, the Netherlands; Netherlands Heart…
  • Global Drug Discovery, Novo Nordisk A/S, Måløv, Denmark.

Förderung

  • Novo Nordisk
  • TNO

Zitieren

APA

Inia, J. A., van Nieuwkoop-van Straalen, A., Jukema, J. W., Rolin, B., Staarup, E. M., Mogensen, C. K., Princen, H. M. G., & van den Hoek, A. M. (2025). Efficacy of a novel PCSK9 inhibitory peptide alone and with evinacumab in a mouse model of atherosclerosis. Journal of Lipid Research. https://doi.org/10.1016/j.jlr.2025.100753

Vancouver

Inia JA, van Nieuwkoop-van Straalen A, Jukema JW, Rolin B, Staarup EM, Mogensen CK, et al. Efficacy of a novel PCSK9 inhibitory peptide alone and with evinacumab in a mouse model of atherosclerosis. Journal of Lipid Research. 2025. doi:10.1016/j.jlr.2025.100753

BibTeX
@article{Inia2025,
  author = {Inia, José A and van Nieuwkoop-van Straalen, Anita and Jukema, J Wouter and Rolin, Bidda and Staarup, Ellen Marie and Mogensen, Christina K and Princen, Hans M G and van den Hoek, Anita M},
  title = {Efficacy of a novel PCSK9 inhibitory peptide alone and with evinacumab in a mouse model of atherosclerosis},
  journal = {Journal of Lipid Research},
  year = {2025},
  doi = {10.1016/j.jlr.2025.100753}
}
Kostenlos starten →